ProText Mobility Inc. (TXTM)
OTC PINK OTC PINK Primary Summary
ProText Mobility Chairman Reports 831.3 Million TXTM Common Shares; Management Reaffirms No Preferred Conversions
Reported holdings increased by 55.6 million shares since May 20; existing preferred-share rights remain unchanged as ProText advances financial reporting and institutional-readiness initiatives. JOHANNESBURG, South Africa, Oct. 13, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – ProText Mobility, Inc. (OTC: TXTM) (“ProTex”) announced that Chairman and President Dr.
Transform Your Press Releases with Strategic Use of Visual Content
Key Formulas for Crafting Engaging Press Releases New York. May 25, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – In today's fast-paced digital world, the effectiveness of a press release can be significantly enhanced through the strategic use of visuals.
ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases
Key Highlights FORT LAUDERDALE, Fla., March 13, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – ProText Mobility Inc. (OTC: TXTM), a biotech company and leader in blockchain-enabled asset tokenization and compliant Real-World Asset (RWA) solutions, is excited to provide an important strategic update to its shareholders and investors.
ProText Mobility Inc. (TXTM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProText Mobility Inc. ever had a stock split?
ProText Mobility Inc. Profile
| Biotechnology Industry | Healthcare Sector | Plooy Du Dylon CEO | OTC PINK Exchange | 74371E204 CUSIP |
| US Country | 30 Employees | - Last Dividend | 20 Feb 2014 Last Split | - IPO Date |
Overview
ProText Mobility, Inc. is a dynamic entity operating within the biotechnology sphere, focusing primarily on the development of pharmaceutical botanical medicines. This innovative company leverages the natural efficacies inherent in plant extracts, enhancing their bioavailability through advanced pharmaceutical methodologies. Based in the vibrant city of Boca Raton, Florida, ProText Mobility stands as a proud subsidiary of Plandaí Biotechnology, Inc., a parent company renowned for its contributions to biotechnological advancements and botanical research. Through its dedication to harnessing the power of nature in medicine, ProText Mobility, Inc. is at the forefront of offering alternative therapeutic options rooted in botanical extracts.
Products and Services
ProText Mobility, Inc. has dedicated its research and development efforts towards creating a portfolio of products that encapsulate the potency of botanical extracts for various therapeutic applications. The products are characterized by their highly-bioavailable plant extracts, ensuring maximum efficacy and absorbability. Here is a list of their key offerings:
- Pharmaceutical Botanical Medicines:
The cornerstone of ProText Mobility's product line, these medicines are developed with an emphasis on leveraging the therapeutic potentials of plant extracts. Through state-of-the-art extraction and formulation techniques, the company ensures that these botanical medicines maintain a high degree of purity and bioavailability, making them more effective and accessible for patients seeking alternative or complementary therapeutic options.
Contact Information
